Press releases

• July 1, 2020 - Regulatory press releaseInvitation to presentation of BioArctic’s Interim Report for the period January – June 2020 on July 10 at 9.30 a.m. CET
• June 29, 2020 - Other press releaseBioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease
• May 26, 2020 - Regulatory press releaseMembers of BioArctic’s Board of Directors and management increase their shareholdings

Archive

Calendar

• July 10, 2020 08:00 CETInterim report January – June 2020
• October 14, 2020 08:00 CETInterim report January – September 2020
• February 4, 2021 08:00 CETFull Year Report January – December 2020

Interim report Q2 2020

BioArctic AB will publish the company’s Interim Report for the period January – June 2020 on Friday, July 10, 2020, at 08:00 a.m. CEST.

• Invitation
• Webcast

Read more

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more